My ePortfolio Register   

Evolving role of MRD negativity in multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.03.17
Views: 1935

Prof Jesús San Miguel - University Hospital, Salamanca, Spain

Professor Jesus San Miguel (University Hospital of Salamanca, Salamanca, Spain) outlines how the role of minimal residual disease (MRD) negativity has evolved to become part of the central narrative of how multiple myeloma is treated.

In the 1980s a cure in multiple myeloma was considered unattainable due to the small proportion of patients achieving a complete response.

However, with the introduction of new agents the landscape has changed.

This movement led to the International Myeloma Working Group recently publishing a consensus criteria for response and minimal residual disease assessment in multiple myeloma.

In this review several aspects of disease response assessment are clarified, as well as endpoints for clinical trials and future directions.

Professor San Miguel adds that while the concept of MRD is usually associated with depth of treatment response in multiple myeloma, there could be growing utility around measuring treatment efficacy with long term follow up, as seen in other diseases.

The impact that MRD negativity has on patients is then discussed, with clear associations between patients being MRD negative and a positive response.

Whilst questions remain, the potential of MRD negativity being a surrogate marker for cure in multiple myeloma is a distinct possibility.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceuticals (A Johnson & Johnson Company).

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence